PT - JOURNAL ARTICLE AU - Justin B. Miller AU - Elizabeth Ward AU - Lyndsay A. Staley AU - Jeffrey Stevens AU - Craig C Teerlink AU - Justina P. Tavana AU - Matthew Cloward AU - Madeline Page AU - Louisa Dayton AU - Alzheimer’s Disease Genetics Consortium AU - Lisa A. Cannon-Albright AU - John S.K. Kauwe TI - Identification and genomic analysis of pedigrees with exceptional longevity identifies candidate rare variants AID - 10.1101/2020.03.02.20030197 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.02.20030197 4099 - http://medrxiv.org/content/early/2020/03/02/2020.03.02.20030197.short 4100 - http://medrxiv.org/content/early/2020/03/02/2020.03.02.20030197.full AB - Background Longevity as a phenotype entails living longer than average and typically includes living without chronic age-related diseases. Recently, several common genetic components to longevity have been identified. This study aims to identify additional rare genetic variants associated with longevity using unique and powerful pedigree-based analyses of pedigrees with a statistical excess of healthy elderly individuals identified in the Utah Population Database (UPDB).Methods From an existing biorepository of Utah pedigrees, four pedigrees were identified which exhibited an excess of healthy elderly individuals; whole exome sequencing (WES) was performed on one set of elderly first- or second-cousins from each pedigree. Rare (<0.01 population frequency) variants shared by at least one elderly cousin pair in a region likely to be identical by descent were identified as candidates. Ingenuity Variant Analysis was used to prioritize putative causal variants based on quality control, frequency, and gain or loss of function. The variant frequency was compared in healthy cohorts and in an Alzheimer’s disease cohort. Remaining variants were filtered based on their presence in genes reported to have an effect on the aging process, aging of cells, or the longevity process. Validation of these candidate variants included tests of segregation to other elderly relatives.Results Fifteen rare candidate genetic variants spanning 17 genes shared within cousins were identified as having passed prioritization criteria. Of those variants, six were present in genes that are known or predicted to affect the aging process: rs78408340 (PAM), rs112892337 (ZFAT), rs61737629 (ESPL1), rs141903485 (CEBPE), rs144369314 (UTP4), and rs61753103 (NUP88 and RABEP1). ESPL1 rs61737629 and CEBPE rs141903485 show additional evidence of segregation with longevity in expanded pedigree analyses (p-values=0.001 and 0.0001, respectively).Discussion This unique pedigree analysis efficiently identified several novel rare candidate variants that may affect the aging process and added support to seven genes that likely contribute to longevity. Further analyses showed evidence for segregation for two rare variants, ESPL1 rs61737629 and CEBPE rs141903485, in the original longevity pedigrees in which they were originally observed. These candidate genes and variants warrant further investigation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe appreciate the contributions of Brigham Young University in supporting this research. This research is supported by RF1AG054052 (PI: Kauwe) and U01AG052411 (PI: Goate). We thank the Pedigree and Population Resource of Huntsman Cancer Institute, University of Utah (funded in part by the Huntsman Cancer Foundation) for its role in the ongoing collection, maintenance and support of the Utah Population Database (UPDB). We also acknowledge partial support for the UPDB through grant P30 CA2014 from the National Cancer Institute, University of Utah and from the University of Utah’s program in Personalized Health and Center for Clinical and Translational Science. The authors would like to thank the NHLBI GO Exome Sequencing Project and its ongoing studies which produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the Heart GO Sequencing Project (HL-103010). Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the UPDB, the ADGC, and the Wellderly study were obtained using the applicable request forms and handled in accordance with IRB-approved methods.